Clinical acceptability study of micronized purified flavonoid fraction 1000 mg tablets versus 500 mg tablets in patients suffering acute hemorrhoidal disease

References

• Corman ML. Colon and Rectal Surgery, 3rd edn. Philadelphia: J.B. Lippincott, 1993
   Google Scholar
• Johanson JF, Sonnenberg A. The prevalence of hemorrhoids and chronic constipation. An epidemiologic study. Gastroenterology 1990;98:380-6
   PubMed Web of Science ®Google Scholar
• Barbe R, Amiel M. Pharmacodynamic properties and therapeutic efficacy of Daflon 500 mg. Phlebology 1992;7(Suppl 2):41-4
   Google Scholar
• Cotonat A, Cotonat J. Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct. Int Angiol 1989;8(Suppl 4):15-18
   PubMed Web of Science ®Google Scholar
• McHale NG, Hollywood MA. Control of lymphatic pumping: interest of Daflon 500 mg. Phlebology 1994;9(Suppl 1):23-5
   Web of Science ®Google Scholar
• Bouskela E, Cyrino FZ, Lerond L. Effects of oral administration of different doses of purified micronized flavonoid fraction on microvascular reactivity after ischemia/reperfusion in the hamster cheek pouch. Br J Pharm 1997;122:1611-16
   PubMed Web of Science ®Google Scholar
• Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;4:391-9
   Web of Science ®Google Scholar
• Friesenecker B, Tsai AG, Allegra C, Intaglietta M. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold. Int J Microcirc 1994;14:50-5
   PubMedGoogle Scholar
• Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc 1997;17(Suppl 1):11-17
   PubMedGoogle Scholar
• Stucker O, Bonhomme E, Lenaers A, Teisseire B. Daflon 500 mg depresses bradykinin-ischemia-induced microvascular leakage of FITC-Dextran in rat cremaster muscle. Int Angiol 1989;8(Suppl 4):39-43
   PubMed Web of Science ®Google Scholar
• Takase S, Lerond L, Bergan JJ, Schmid-Schönbein GW. The inflammatory reaction during venous hypertension in the rat. Microcirculation 2000;7:41-52
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson K, Perry CM. Micronised purified flavonoid fraction. A review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63:71-100
   PubMed Web of Science ®Google Scholar
• Misra MC. Drug treatment of haemorrhoids. Drugs 2005;65:1481-91
   PubMed Web of Science ®Google Scholar
• Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute haemorroids. Phlebology 1994;(Suppl 1):40-3
   Web of Science ®Google Scholar
• Jiang ZM, Cao JD. The impact of micronized purified flavonoid fraction on the treatment of acute haemorrhoidal episodes. Curr Med Res Opin 2006;22:1141-7
   PubMed Web of Science ®Google Scholar
• Vajrabukka T. Study of the therapeutic activity of Daflon 500 mg in acute episode of haemorrhoids. A controlled, double-blind trial of Daflon 500 mg against placebo with a treatment of 7 days. Clinical report. 1993
   Google Scholar
• Misra MC, Parshad R. Randomized clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemorrhoids. Br J Surg 2000;87:868-72
   PubMed Web of Science ®Google Scholar
• Elbaz C. Efficacy study of Daflon 500 mg in 1931 patients presenting with chronic venous insufficiency. Gaz Med Fr 1989;96(39 Suppl):30-2
   Google Scholar
• Meyer OC. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease. Angiology 1994;45:579-84
   PubMed Web of Science ®Google Scholar
• Menyhei G, Ascady G, Hetenyi A, et al. Chronobiology and clinical activity of Daflon 500 mg in chronic venous insufficiency. Phlebology 1994;9(Suppl 1):15-18
   Web of Science ®Google Scholar
• Ramelet AA, Boisseau MR, Allegra C, et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005;33:309-19
   PubMed Web of Science ®Google Scholar
• Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo. Angiology 1994;45:574-8
   PubMed Web of Science ®Google Scholar
• Delmont J, Ljunggren B, De Champvallins M, Granger C. Assessment of the acceptability and efficacy of Daflon 500 mg in the long-term treatment (six months) of haemorrhoids. Int J Clin Pract (Hong Kong) 1992;8:14-18
   Google Scholar
• Frileux C, Meynadier J, Ortonne JP. Sécurité d’emploi et maintien de l’efficacité de Daflon 500 mg en traitement prolongé. JIM 1987;99(Suppl):40-1
   Google Scholar
• Jantet G; RELIEF Study Group. Chronic venous insufficiency: worldwide results of the RELIEF study. Angiology 2002;53:245-56
   PubMed Web of Science ®Google Scholar
• Navratilova Z. Efficacy of Detralex in venous oedema treatment – EDET study results. Interni Med 2009;11:87-90
   Google Scholar
• Pointel JP, Mallet C, De Champvallins M, Mocatti D. Treatment of functional venous insufficiency with Daflon 500 mg for one year: therapeutic benefits, clinical and biological acceptability. Artères Veines 1988;7:197-201
   Google Scholar
• Buckshee K, Takkar D, Aggarwal N. Micronized flavonoid therapy in internal hemorrhoids of pregnancy. Int J Gynecol Obstet 1997;57:145-51
   PubMed Web of Science ®Google Scholar
• Mukherjee GG, Gajaraj AJ, Mathias J, Marya D. Treatment of abnormal uterine bleeding with micronized flavonoids. Int J Gynecol Obstet 2005;89:156-7
   PubMed Web of Science ®Google Scholar
• Greney P. Venous insufficiency: confirmation by 580 private gynaecologists of the efficacy of Daflon 500 mg in leg pain due to trophic disorders. J Int Med 1992;257:108-10
   Google Scholar
• Boccalon H, Salvadori C, Benedittini D, et al. Therapeutic equivalence of two dosage forms of a micronized flavonoid fraction in patients with chronic venous insufficiency. Curr Ther Res Clin Exp 1996;57:757-66
   Web of Science ®Google Scholar
• Dimitroulopoulos D, Tsamakidis K, Xinopoulos D. Prospective, randomized, controlled, observer-blinded trial of combined infrared photocoagulation and micronized purified flavonoid fraction versus each alone for the treatment of hemorrhoidal disease. Clin Ther 2005;27:746-54
   PubMed Web of Science ®Google Scholar
• Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009;15:e22-33
   PubMed Web of Science ®Google Scholar